替羅非班橋接雙聯抗血小板治療急性腦梗死的療效及安全性

曹曉攀

[關鍵詞] 急性腦梗死;抗血小板治療;拜阿司匹林;氯吡格雷;替羅非班

[中圖分類號] R542.22? ? ? ? ? [文獻標識碼] B? ? ? ? ? [文章編號] 1673-9701（2021）20-0054-04

The efficacy and safety of bridging dual antiplatelet therapy with tirofiban in acute cerebral infarction

CAO Xiaopan

Department Ⅲ of Internal Medicine-Neurology，the First People′s Hospital of Shenyang City，Shenyang? ?110041，China

[Abstract] Objective To analyze and investigate the clinical efficacy and treatment safety of bayaspirin and clopidogrel dual antiplatelet therapy combined with tirofiban for patients with acute cerebral infarction. Methods All 90 patients with acute cerebral infarction admitted to our department from March 2018 to March 2019 were selected according to odd and even medical record number， and they were divided into the observation group and the control group， with 45 cases in each group. Both groups were given bayaspirin and clopidogrel combined with dual antiplatelet therapy， while the observation group was given tirofiban combined with intravenous injection therapy before conventional medication. The activities of daily living （ADL）， the improvement of neurological function and the safety of patients after treatment were compared. Results After half a month， the total efficacy rates in the observation group was 91.11%，which was higher than that of 66.67% in the control group， and the difference was statistically significant （P<0.05）. The NIHSS scores in the observation group after 3 days and half a month were （9.08±0.29） points and （6.37±0.25） points， which were significantly lower than those of （10.28±0.43） points and （8.34±0.28） points in the control group，and the differences were statistically significant （P<0.05）. The ADL scores in the observation group after 3 days and half a month were （43.97±2.03） points and （55.19±3.03） points in the observation group， which were significantly higher than those of （35.99±1.92） points and （45.39±2.43） points in the control group， and the differences were statistically significant （P<0.05）. There was no statistically significant difference in the total incidence of adverse events between the two groups （P>0.05）. Conclusion The combination of bayaspirin and clopidogrel dual antiplatelet therapy combined with tirofiban in patients with acute cerebral infarction has relatively higher clinical application value and higher therapeutic safety.

[Key words] Acute cerebral infarction;Antiplatelet therapy;Bayaspirin;Clopidogrel;Tirofiban